Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report Abstract #436

Introduction: Merkel cell carcinoma (MCC) is a relatively rare neuroendocrine malignant tumor that is characterized by an aggressive course with regional nodal involvement, distant metastases and a high rate of recurrence.
Aim(s): To present a case of successful treatment of MCC.
Materials and methods: A 46-year-old female patient was referred for evaluation of a mass in the soft tissue of the left thigh. Tumor mass (8x12cm) and inguinal adenopathy were found. A wide excision and inguinofemoral lymphadenectomy of the left side were performed in December 2009. In immunohistochemical examination, the tumor cells showed diffuse positivity for Chromogranin A (CgA) and a characteristic dot-like staining for cytokeratin 20, Ki-67 – 50%. Diagnosis of MCC was established. Paraaortal adenopathy was diagnosed by CT scan in January 2010. Blood levels of CgA and serotonin were 33.2 U/L (N–2-18) and 425.2 ng/ml (N–30-200), respectively. The patient received six cycles of CT with cisplatin (70mg/m2 day 1) and etoposide (120mg/m2 days 1-3) since February to July 2010. Therapy with SS analogues (Sandostatin LAR 20mg every 28days) was started in March 2010.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Orlova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#428 Clinical Manifestations of Patients with Pancreatic ß Cells Hyperplasia
Introduction: Pathologic hyperplasia of pancreatic endocrine cells is uncommon. ß cell hyperplasia contributes to persistent hyperinsulinemic hypoglycemia. The manifestations of patients with pancreatic ß cells hyperplasia are variable and their preop. diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Tsann Long Hwang
#1375 Merkel Cell Carcinoma of the Knee Treated with Somatostatin Analogue and Radiotherapy: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ivana Puliafito
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#1129 Expression and Clinical Significance of Merkel Cell Polyomavirus Large T Antigen in Merkel Cell Carcinoma
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is often associated with Merkel cell polyomavirus (MCPyV) infection. MCPyV expression and its relationship with clinical features and prognosis in MCC remain unclear.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Vera Delektorskaya
#2909 Serotonin-Secreting NeuroEndocrine Neoplasms of the Pancreas: Which Are the Primary Pancreatic Carcinoids?
Introduction: Serotonin-secreting pancreatic neuroendocrine neoplasms (5-HT-secreting pNENs) are very rare. They are characterised by high urinary 5-hydroxyindole-acetic acid (5-HIAA) levels (or high serum 5-HT levels).
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team